NasdaqGS:MRNABiotechs
Assessing Moderna (MRNA) Valuation After Promising Melanoma Vaccine Data With Keytruda
Recently released five year phase 2b data on Moderna (MRNA) and Merck’s personalized melanoma vaccine with Keytruda showed a 49% reduction in recurrence or death, sparking fresh interest in Moderna’s push into oncology.
See our latest analysis for Moderna.
The melanoma vaccine update arrives after a sharp rebound in Moderna’s share price, with a 90 day share price return of 89.31% and a 1 month share price return of 53.81%. However, the 3 year total shareholder return of negative 73.47% and 5...